# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 51-60 of 2194 results.
Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
Status: Completed
Last Changed: Apr 18, 2016
First Received: Jun 09, 2011
Disease(s): Diffuse Large B-cell Lymphoma
Locations: Hospital de Elda, Elda, Alicante, Spain
Hospital de Cabueñes, Gijón, Asturias, Spain
H. U. Central de Asturias, Oviedo, Asturias, Spain
H. U. Germans Trias i Pujol, Badalona, Barcelona, Spain
Hospital General de Granollers, Granollers, Barcelona, Spain
... and 52 other locations.
A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients
Status: Unknown status
Last Changed: Dec 11, 2015
First Received: Feb 18, 2013
Disease(s): Diffuse Large B-cell Lymphoma
Locations: Tumor center, Sun Yat-sen University, Guangzhou, Guangdong, China
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
Status: Not yet recruiting
Last Changed: Jun 11, 2020
First Received: Nov 01, 2019
Disease(s): Non-Hodgkin's B-cell Lymphoma
Intervention(s): DZD9008
Locations: Jiangsu Province Hospital - Haematology, Nanjing, China
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Status: Recruiting
Last Changed: Apr 01, 2020
First Received: Apr 11, 2016
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Chidamide, Vinorelbine, Liposomal Doxorubicin or mitoxantrone, Dexamethasone, Thalidomide
Locations: Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
Status: Recruiting
Last Changed: Mar 11, 2020
First Received: Aug 14, 2018
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Tisagenlecleucel, Pembrolizumab
Locations: Emory University School of Medicine SC CTL019, Atlanta, Georgia, United States
University of Chicago Medical Center Hematology and Oncology, Chicago, Illinois, United States
University of Kansas Hospital and Medical Center U of Kansas Cancer Center, Kansas City, Kansas, United States
University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
Novartis Investigative Site, Wien, Austria
... and 3 other locations.
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Not yet recruiting
Last Changed: May 12, 2020
First Received: May 12, 2020
Disease(s): Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Intervention(s): Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin
Risk Adapted Therapy in Diffuse Large B Cell Lymphoma
Status: Unknown status
Last Changed: Jul 06, 2017
First Received: Jun 15, 2017
Disease(s): Large B Cell Lymphoma
Intervention(s): rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim
Locations: Oncology center, Mansoura, Egypt
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
Status: Recruiting
Last Changed: Jan 21, 2020
First Received: Mar 15, 2019
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Tisagenlecleucel, Ibrutinib
Locations: Stanford University, Palo Alto, California, United States
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients
Status: Unknown status
Last Changed: Jun 28, 2011
First Received: Feb 18, 2009
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): NKM injection
Locations: The Catholic University of korea, Banpo-Dong 505, Seoul, Korea, Republic of
Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)
Status: Completed
Last Changed: May 29, 2018
First Received: Sep 17, 2008
Disease(s): Diffuse Large B-cell Lymphoma
Locations: Weill Cornell Medical College, New York, New York, United States